CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

American Well Q3 revenue beats estimates on subscriptions, AMG

By Reuters News


Overview

  • US SaaS healthcare platform's Q3 revenue rose and beat analyst expectations

  • Company posted Q3 net loss of $11.0 mln

  • Company raised 2026 revenue and adjusted EBITDA outlook


Outlook

  • Amwell raises 2026 revenue outlook to $204 mln-$206 mln from $200 mln-$205 mln

  • Amwell raises 2026 adjusted EBITDA outlook to ($8) mln-($7) mln from ($9) mln-($7) mln

  • Company expects 2026 AMG visits between 1.32 mln and 1.37 mln


Result Drivers

  • SUBSCRIPTION AND VISIT REVENUE - Co said Q3 revenue was driven by subscription revenue of $23.9 mln and Amwell Medical Group visit revenue of $23.7 mln

  • MEMBER ENGAGEMENT - Co said activating more members and simplifying their experience contributed to Q3 results


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$48.99 mln

$47.29 mln (6 Analysts)

Q3 Loss Per Share

$0.67


Analyst Coverage

  • The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 1 "strong buy" or "buy", 8 "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the healthcare facilities & services peer group is "buy."

  • Wall Street's median 12-month price target for American Well Corporation is $12.00, about 4.2% below its November 2 closing price of $12.52


Reuters Recommended Reads

  • Nov 2 - Waystar Q3 revenue, adjusted profit beat estimates on subscription growth

  • Nov 2 - HealthStream Q3 revenue, adjusted EBITDA beat estimates; raises 2026 outlook

  • Nov 3 - Varonis Q3 revenue rises 17%, beats analyst expectations


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.